Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets

• Gennisium finds a strategic companion with international expertise and connections in the pharmaceutical trade to speed up its improvement in neonatology.
• Pierre Fabre strengthens its actions in the sphere of uncommon illnesses, and extra particularly pediatric ones.
• This partnership paves the best way for additional collaboration between the 2 corporations and marks a milestone for their respective development technique in neonatology/pediatrics, uncommon illnesses and niche/orphan medicine.

CASTRES, France and VITROLLES, France, Oct. 10, 2022 /PRNewswire/ — The Pierre Fabre Group and Gennisium Pharma have introduced an settlement whereby Pierre Fabre takes a minority stake in Gennisium by its dedicated investment subsidiary Pierre Fabre Invest.

Gennisium’s company mission is to offer new child sufferers with appropriate medicines, based mostly on reasonably priced costs and with international attain. To this finish, Gennisium is seeking to reposition recognized molecules for neonatal indications and to offer well being care professionals and neonatal intensive care items with novel and appropriate formulations together with the medicines they should stop or deal with neonatal illnesses and situations.

Franck Pigache, CEO, Gennisium Pharma, commented: “We are very pleased with this investment and to now have such a strong partner as Pierre Fabre among our shareholders – a major player and a successful company with solid experience in the pharmaceutical industry and the specific field of pediatrics. With their backing, Gennisium will have additional means and latitude to pursue its growth. New drugs are under development and Pierre Fabre’s investment will allow us to accelerate the registration and availability of those products.”

Alongside oncology and dermatology, Pierre Fabre is more and more concerned in the sphere of uncommon illnesses, with a particular concentrate on illnesses affecting newborns, creating particular and prophylactic therapies for this affected person inhabitants in want for tailored therapies. Such is the method adopted for childish hemangioma since 2014 and, extra not too long ago, for XLHED, a uncommon genetic illness affecting the sweat and respiratory glands, pores and skin, hair and enamel situations of child boys.      

Eric Ducournau, CEO, Pierre Fabre Group, stated: “We are delighted to be working with Gennisium Pharma, a young, innovative pharmaceutical company developing formulations for premature babies and niche markets. Through this investment, we confirm our willingness to explore new opportunities in the field of rare pediatric diseases where patient and family needs remain immense.“

Both corporations are already working collectively to offer this fragile inhabitants of sufferers with therapeutic advances. By becoming a member of forces with Pierre Fabre, Gennisium finds a sturdy companion with international expertise and connections in the pharmaceutical trade to speed up its improvement in neonatology. Pierre Fabre will assist Gennisium construct up its product portfolio, its group and its market entry internationally, by investing in current operations, potential licensing agreements and experience sharing in the sphere of neonatology and pediatrics.

For extra details about Pierre Fabre, please go to the web site www.pierre-fabre.com

For extra details about Gennisium, please go to the web site https://gennisium.com

Pierre Fabre 

Anne KERVEILLANT                                           

anne.kerveillant@pierre-fabre.com              

Lys Avocat

Siham Belarbi 

s.belarbi@lysavocats.com

Gennisium Pharma

Frank PIGACHE, CEO 

fpigache@gennisium.com

Logo – https://mma.prnewswire.com/media/1916090/Pierre_Fabre_Gennisium__Logo.jpg

View unique content material:https://www.prnewswire.co.uk/news-releases/pierre-fabre-is-taking-a-minority-stake-via-its-dedicated-investment-subsidiary-pierre-fabre-invest-in-gennisium-pharma-an-innovative-company-specializing-in-medicines-for-premature-newborns-and-niche-markets-301643662.html

Source link